Hypera SA
BOVESPA:HYPE3

Watchlist Manager
Hypera SA Logo
Hypera SA
BOVESPA:HYPE3
Watchlist
Price: 18.53 BRL -0.64%
Market Cap: 11.7B BRL
Have any thoughts about
Hypera SA?
Write Note

Gross Margin
Hypera SA

61%
Current
63%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
61%
=
Gross Profit
4.7B
/
Revenue
7.8B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
BR
Hypera SA
BOVESPA:HYPE3
11.7B BRL
61%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
US
Eli Lilly and Co
NYSE:LLY
756.2B USD
81%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
85%
US
Johnson & Johnson
NYSE:JNJ
351.2B USD
69%
US
Merck & Co Inc
NYSE:MRK
251.2B USD
77%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
73%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
82%
CH
Novartis AG
SIX:NOVN
171.5B CHF
75%
US
Pfizer Inc
NYSE:PFE
151.1B USD
71%
Country BR
Market Cap 11.7B BRL
Gross Margin
61%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 756.2B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 351.2B USD
Gross Margin
69%
Country US
Market Cap 251.2B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 151.1B USD
Gross Margin
71%
No Stocks Found

Hypera SA
Glance View

Market Cap
11.7B BRL
Industry
Pharmaceuticals

Hypera S.A., a leading force in the Brazilian pharmaceuticals market, has carved a niche by catering to a wide spectrum of health needs through a diverse portfolio. Originally established under the name Hypermarcas, the company took root with the ambition of becoming a pharmaceutical powerhouse in Brazil. This vision was set in motion through strategic organic growth and a series of savvy acquisitions, which helped consolidate its offerings across over-the-counter (OTC) medications, branded prescriptions, dermo-cosmetics, and generics. Each of these segments represents a cog in the machine that drives Hypera’s profitability, with its robust pipeline of drug innovations and strong brand presence ensuring a steady flow of revenue. What truly sets Hypera apart is its ability to harness the synergies between its diverse product lines and an extensive distribution network across Brazil. The company generates revenue not only by selling pharmaceuticals directly to consumers but also through collaborations with healthcare professionals and pharmacies, ensuring its products reach a vast market. Hypera’s commitment to research and development further fuels its growth engine, as it continuously seeks to introduce new drugs and treatments that meet the evolving healthcare demands. The company’s strategic focus on operational efficiency and cost management underpins its financial performance, while its strong brand recognition makes it a preferred choice among consumers and medical professionals alike in Brazil’s dynamic healthcare environment.

HYPE3 Intrinsic Value
38.95 BRL
Undervaluation 52%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
61%
=
Gross Profit
4.7B
/
Revenue
7.8B
What is the Gross Margin of Hypera SA?

Based on Hypera SA's most recent financial statements, the company has Gross Margin of 61%.